Free Trial
NASDAQ:SLRN

Acelyrin (SLRN) Stock Price, News & Analysis

$6.90
+0.09 (+1.32%)
(As of 07/23/2024 ET)
Today's Range
$6.81
$7.06
50-Day Range
$3.86
$7.06
52-Week Range
$3.67
$29.88
Volume
975,254 shs
Average Volume
1.08 million shs
Market Capitalization
$683.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.80

Acelyrin MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
85.5% Upside
$12.80 Price Target
Short Interest
Bearish
11.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.47mentions of Acelyrin in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$7 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.33) to ($4.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

615th out of 897 stocks

Pharmaceutical Preparations Industry

287th out of 426 stocks

SLRN stock logo

About Acelyrin Stock (NASDAQ:SLRN)

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

SLRN Stock Price History

SLRN Stock News Headlines

Jeff Bezos’s Terrifying New Technology
Please understand — if you thought AI was a threat, just wait until you see what Jeff Bezos has done with QaaS. 99% of Americans have no idea what’s about to happen. What humanity is about to witness is the greatest tech disruption of all time.
Acelyrin, Inc. (SLRN)
SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024
Acelyrin Founder Steps Down as CEO
Jeff Bezos’s Terrifying New Technology
Please understand — if you thought AI was a threat, just wait until you see what Jeff Bezos has done with QaaS. 99% of Americans have no idea what’s about to happen. What humanity is about to witness is the greatest tech disruption of all time.
ACELYRIN, INC. Announces Leadership Transition
SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023
See More Headlines
Receive SLRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acelyrin and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/14/2024
Today
7/24/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLRN
Fax
N/A
Employees
135
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.80
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+85.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-381,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.74 per share

Miscellaneous

Free Float
85,559,000
Market Cap
$683.31 million
Optionable
Optionable
Beta
2.55
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Melanie Gloria B.S.N. (Age 46)
    Chief Operating Officer
    Comp: $667.52k
  • Ms. Mina Kim (Age 50)
    CEO & Director
  • Mr. Gilbert M. Labrucherie J.D. (Age 52)
    CFO & Chief Business Officer
  • Mr. Tyler Marciniak
    Head of Investor Relations & Communications
  • Ms. Sanam Pangali J.D.
    Chief Legal Officer & Head of People
  • Dr. Paul M. Peloso M.D. (Age 66)
    M.Sc., Chief Medical Officer
  • Ms. Suzy Buckhalter CPA
    Senior Director of Finance & Accounting
  • Mr. Kenneth A. Lock (Age 50)
    Chief Commercial Officer
  • Dr. Shephard Mpofu M.D.
    Chief Medical Officer
  • Ms. Patricia A. Turney (Age 57)
    Chief Technical Operations Officer

SLRN Stock Analysis - Frequently Asked Questions

How have SLRN shares performed this year?

Acelyrin's stock was trading at $7.46 at the beginning of 2024. Since then, SLRN shares have decreased by 7.5% and is now trading at $6.90.
View the best growth stocks for 2024 here
.

How were Acelyrin's earnings last quarter?

Acelyrin, Inc. (NASDAQ:SLRN) issued its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.93) by $0.57.

When did Acelyrin IPO?

Acelyrin (SLRN) raised $540 million in an initial public offering on Friday, May 5th 2023. The company issued 30,000,000 shares at $18.00 per share.

Who are Acelyrin's major shareholders?

Acelyrin's top institutional shareholders include Nisa Investment Advisors LLC (0.01%) and SG Americas Securities LLC (0.01%). Insiders that own company stock include Biopartners Fund Ii Westlake, Shao-Lee Lin, Beth C Seidenberg, Daniel J Becker and Ronald Oyston.
View institutional ownership trends
.

How do I buy shares of Acelyrin?

Shares of SLRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLRN) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners